The Human SARS Coronavirus 2 RNA Dependent RNA Polymerase pipeline drugs market research report outlays comprehensive information on the Human SARS Coronavirus 2 RNA Dependent RNA Polymerase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Human SARS Coronavirus 2 RNA Dependent RNA Polymerase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Infectious Disease which include the indications Coronavirus Disease 2019 (COVID-19), and Respiratory Syncytial Virus (RSV) Infections. It also reviews key players involved in Human SARS Coronavirus 2 RNA Dependent RNA Polymerase targeted therapeutics development with respective active and dormant or discontinued products.

The Human SARS Coronavirus 2 RNA Dependent RNA Polymerase pipeline targets constitutes close to 14 molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical, and Discovery stages are 1, 3, 2, 2, and 2 respectively. Similarly, the universities portfolio in Phase I, and Discovery comprises 1, and 3 molecule.

Human SARS Coronavirus 2 RNA Dependent RNA Polymerase overview

Human SARS coronavirus 2 RNA dependent RNA polymerase (RdRp) is an improtant enzyme for viral RNA replication. RdRp, also known as Nsp12, exhibits significant polymerase activities with the assistance of other cofactors, nsp7 and nsp8, while Nsp12 itself shows limited or no catalytic activity.

For a complete picture of Human SARS Coronavirus 2 RNA Dependent RNA Polymerase’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.